Comparative Pharmacology
Head-to-head clinical analysis: OGEN 625 versus OGEN 5.
Peer-Reviewed Evidence
Head-to-head clinical analysis: OGEN 625 versus OGEN 5.
OGEN .625 vs OGEN 5
Head-to-head clinical comparison of therapeutic indices and safety profiles.
Estrogen replacement therapy; estrogen binds to estrogen receptors, which then translocate to the nucleus and modulate gene transcription, leading to effects such as proliferation of the endometrium and regulation of gonadotropin secretion.
Estrogen replacement; binds to estrogen receptors, activating gene transcription for estrogenic effects in target tissues.
Treatment of moderate to severe vasomotor symptoms due to menopauseTreatment of vulvar and vaginal atrophy due to menopausePrevention of postmenopausal osteoporosis
Treatment of moderate to severe vasomotor symptoms associated with menopauseTreatment of vulvar and vaginal atrophy associated with menopausePrevention of postmenopausal osteoporosis
0.625 mg orally once daily
0.625 mg orally once daily, adjusted based on response.
None Documented
None Documented
Estrone: 10-24 hours; equilin: 12-18 hours; terminal half-life supports once-daily dosing.
Terminal elimination half-life of estrone (primary active metabolite) is approximately 20 hours; steady-state concentrations achieved within 6-8 days. Half-life of estradiol is shorter (1-2 hours) but clinically the estrogenic effect correlates with estrone.
Primarily metabolized in the liver via CYP3A4; undergoes first-pass metabolism including sulfation and glucuronidation. Estropipate is hydrolyzed to estradiol and then metabolized.
Primarily hepatic metabolism via CYP3A4 and other CYP enzymes; undergoes enterohepatic recirculation.
Renal (primarily as glucuronide and sulfate conjugates, ~50-80% of a dose), fecal (~10-20%), with enterohepatic recirculation.
Renal (primarily as conjugated metabolites); approximately 50-80% of an oral dose is excreted in urine, with about 20% in feces via biliary elimination.
~50-80% bound to sex hormone-binding globulin (SHBG) and albumin.
Estrone and estradiol: approximately 98% bound to sex hormone-binding globulin (SHBG) and albumin.
Estrone: ~1-2 L/kg; indicates extensive tissue distribution.
Volume of distribution for estrogens: approximately 20 L/kg; indicates extensive distribution into tissues, including fat and reproductive organs.
Oral: ~30-50% due to first-pass metabolism; micronized formulation enhances absorption.
Oral estrone sulfate: approximately 30-50% due to first-pass metabolism in the liver and gut; interindividual variability due to differences in hydrolysis and conjugation.
No dose adjustment required for GFR ≥30 mL/min; insufficient data for GFR <30 mL/min, use with caution
No dose adjustment required for mild-to-moderate renal impairment; contraindicated in severe renal impairment.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: contraindicated
No specific guidelines; caution in severe hepatic disease.
Not indicated for use in pediatric patients
Not approved for use in pediatric patients.
Use lowest effective dose; monitor for thromboembolic events and malignant neoplasms; no specific dose adjustment recommended
Use lowest effective dose; monitor for thromboembolic events and malignancy.
Estrogens increase the risk of endometrial carcinoma in postmenopausal women. Also, estrogens should not be used to prevent cardiovascular disease or dementia. Increased risks of myocardial infarction, stroke, invasive breast cancer, pulmonary emboli, and deep vein thrombosis have been reported with estrogen-alone therapy.
Estrogens increase the risk of endometrial cancer in women with an intact uterus. Unopposed estrogen use is associated with an increased risk of endometrial hyperplasia and carcinoma. Cardiovascular disorders, breast cancer, and probable dementia have also been reported with estrogen therapy.
Increased risk of endometrial cancer; cardiovascular disorders (MI, stroke, VTE); probable dementia; breast cancer; gallbladder disease; hypercalcemia; fluid retention; visual abnormalities; hereditary angioedema; exacerbation of asthma, diabetes, epilepsy, migraine, porphyria, SLE, and hepatic hemangiomas; hypothyroidism; elevated triglycerides; and hypersensitivity reactions.
Cardiovascular disorders (e.g., stroke, DVT, pulmonary embolism), probable dementia (increased risk in women aged 65 years or older), breast cancer, endometrial cancer, gallbladder disease, hypercalcemia, visual abnormalities, and exacerbation of endometriosis.
Undiagnosed abnormal genital bleeding; known, suspected, or history of breast cancer; known or suspected estrogen-dependent neoplasia; active or past history of venous thromboembolism; active or recent arterial thromboembolic disease (e.g., stroke, MI); liver dysfunction or disease; known hypersensitivity to estrogens; known protein C, protein S, or antithrombin deficiency; and pregnancy.
Undiagnosed abnormal genital bleeding, known or suspected breast cancer (except in appropriately selected patients being treated for metastatic disease), known or suspected estrogen-dependent neoplasia, active or past history of venous thromboembolism, active or past history of arterial thromboembolism, known or suspected pregnancy, known liver dysfunction or disease, and known hypersensitivity to any component of the product.
Data Pending Review
Data Pending Review
Grapefruit juice may increase estrogen levels; avoid large quantities. No other significant food interactions.
Grapefruit juice may inhibit CYP3A4 metabolism of estrogens, increasing drug levels. Avoid concurrent consumption. No other significant food interactions reported. Maintain adequate calcium and vitamin D intake for bone health.
First trimester: Estrogens are associated with a potential risk of fetal genital tract abnormalities, including congenital anomalies such as hypospadias and vaginal adenosis. Use is contraindicated in pregnancy. Second and third trimesters: Exposure may increase risk of fetal urogenital tract abnormalities, and estrogens have been linked to an elevated risk of vaginal clear cell adenocarcinoma in female offspring. Overall, use is contraindicated throughout pregnancy due to known fetal risks.
Estrogen use during pregnancy is contraindicated. First trimester exposure associated with vaginal adenosis and clear cell adenocarcinoma in female offspring; second and third trimester use may cause urogenital anomalies and feminization of male fetuses. Risk of fetal harm is established.
Estropipate (ogen) is excreted into human breast milk. The milk-to-plasma ratio (M/P ratio) is not established in published literature. Exogenous estrogens may reduce milk production and quality, particularly in early postpartum. Use during breastfeeding is generally not recommended due to potential adverse effects on the infant, including jaundice and long-term effects on reproductive development. Alternative therapies should be considered.
Estrogens are excreted in breast milk; M/P ratio not specified. May reduce milk quantity and quality. Not recommended during breastfeeding.
Estropipate is contraindicated in pregnancy. Pharmacokinetic changes in pregnancy (e.g., increased volume of distribution, altered hepatic metabolism) are not relevant due to absolute contraindication. No dose adjustments are applicable as the drug should not be used.
Contraindicated in pregnancy; no dose adjustments applicable.
Category C
Category C
OGEN 0.625 mg (estropipate) is a conjugated estrogen tablet for hormone therapy. It may increase risk of endometrial cancer; use with progestin in women with intact uterus. Monitor for thromboembolic events. Not for prevention of cardiovascular disease or dementia. Avoid in pregnancy.
OGEN 5 (estropipate) is an esterified estrogen tablet (0.75 mg estropipate equivalent to 0.625 mg conjugated estrogens) used for menopausal hormone therapy. It has a slower absorption and a more stable serum estradiol level compared to conjugated equine estrogens. Monitor for endometrial hyperplasia when used without progestin in women with an intact uterus. Contraindicated in history of breast cancer, thromboembolic disorders, and liver disease.
Take exactly as prescribed; do not skip doses or stop without consulting your doctor.Report any unusual vaginal bleeding, chest pain, shortness of breath, or vision changes immediately.Avoid smoking as it increases risk of blood clots.Inform all healthcare providers that you are taking estrogen.Regular breast exams and mammograms are recommended.
Take this medication exactly as prescribed; do not skip doses.Report any unusual vaginal bleeding, breast lumps, or signs of blood clots (sudden chest pain, shortness of breath, leg swelling) immediately.Avoid grapefruit juice as it may increase estrogen levels.This medication does not protect against sexually transmitted infections or HIV.Inform your healthcare provider if you smoke, as smoking increases the risk of blood clots.Routine mammograms and pelvic exams are recommended while on this therapy.